The estimated Net Worth of Investments, Lpwong Roderic... is at least 575 百万$ dollars as of 6 October 2022. Investments Roderic owns over 1,355,932 units of Tarsus Pharmaceuticals stock worth over 560,588,431$ and over the last 6 years Investments sold TARS stock worth over 14,547,176$.
Investments has made over 26 trades of the Tarsus Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently Investments bought 1,355,932 units of TARS stock worth 19,999,997$ on 6 October 2022.
The largest trade Investments's ever made was buying 1,557,346 units of Tarsus Pharmaceuticals stock on 7 September 2022 worth over 13,564,484$. On average, Investments trades about 235,154 units every 34 days since 2019. As of 6 October 2022 Investments still owns at least 17,628,567 units of Tarsus Pharmaceuticals stock.
You can see the complete history of Investments Roderic stock trades at the bottom of the page.
Over the last 4 years, insiders at Tarsus Pharmaceuticals have traded over 38,362,333$ worth of Tarsus Pharmaceuticals stock and bought 1,047,656 units worth 16,525,269$ . The most active insiders traders include Investments, Lpwong Roderic...、Capital Ix, Llc Vivo Capita...、William J Phd Link. On average, Tarsus Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of 729,047$. The most recent stock trade was executed by William J Phd Link on 12 August 2024, trading 35,000 units of TARS stock currently worth 912,800$.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Tarsus Pharmaceuticals executives and other stock owners filed with the SEC include: